by
Genentech, a member of the Roche Group, this summer announced their own collaboration with Cambridge, MA-based GNS Healthcare. GNS Healthcare’s mission statement is to use the latest innovations in machine learning to turn biomedical data into solutions and treatments.
This collaboration’s first focus will also be on oncology, just like the IBM/Pfizer deal. Genentech plans to use the GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to find and validate potential new drug candidates. They will also look for genetic patient response markers that could lead to targeted therapies.
Read the full article here.